LGALS1 and hepatocellular carcinoma: The study further analyzed the significant miR-22-Gal-1 axis in HCC treatment by comparing the effects of increased miR-22 and Gal-1 silencing, as well as Gal-1 inhibition using LLS30, a small molecule.